Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 5;18(6):6766–6774. doi: 10.3892/ol.2019.11051

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Tao et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 2. — Comparison of OS and RFS between FRGs and DRGs in patients with FLT3-ITD-mutated AML. OS in (A) FRGs alone, (C) DRGs alone or (E) compared with each other, with an FLT3-ITD mutation. OS was significantly longer in patients with an FLT3-ITD mutation combined with FRGs (P=0.0361). There were no significant differences in OS between the patients with a single FLT3-ITD mutation and the patients with DRGs (P=0.8549). RFS in (B) FRGs or (D) DRGs combined with an FLT3-ITD mutation, or (F) the two compared with each other. RFS were significantly longer in patients with an FLT3-ITD mutation combined with FRGs (P=0.0426), but no significant differences in RFS were observed between the patients with a single FLT3-ITD mutation and those with DRGs (P=0.7879). OS, overall survival; RFS, recurrence free survival; FRGs, favorable-risk genes; DRGs, adverse-risk genes; AML, acute myeloid leukemia; FLT3-ITD, FMS-like tyrosine kinase 3-internal tandem duplication mutation.